Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Ligand Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 58

Market Cap: -

Website

Introduction: Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

Clinical Trials

Comparison of Captisol-Enabled™ Iohexol and Omnipaque™ in Patients With Impaired Renal Function Undergoing Coronary Angiography

Phase 2

Withdrawn

Conditions: Contrast-induced Nephropathy

Interventions: Drug: CE-Iohexol
Drug: Iohexol

First Posted Date: 2020-11-13

Last Posted Date: 2022-04-11

Lead Sponsor: Ligand Pharmaceuticals

Registration Number: NCT04627831

A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: LGD-6972-15 mg
Drug: LGD-6972-10 mg
Other: Placebo
Drug: LGD-6972-5 mg

First Posted Date: 2016-08-02

Last Posted Date: 2018-01-12

Lead Sponsor: Ligand Pharmaceuticals

Target Recruit Count: 148

Registration Number: NCT02851849

A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus (T2DM)

Interventions: Drug: LGD-6972 Solution
Drug: LGD-6972 Capsules

First Posted Date: 2016-02-03

Last Posted Date: 2016-05-18

Lead Sponsor: Ligand Pharmaceuticals

Target Recruit Count: 12

Registration Number: NCT02672839

Locations: 🇺🇸
Medpace, Inc, Cincinnati, Ohio, United States

Safety and Tolerability Study of Oral LGD-6972 for Type 2 Diabetes Mellitus

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: LGD-6972
Drug: Placebo (Captisol ®)

First Posted Date: 2014-09-26

Last Posted Date: 2015-06-11

Lead Sponsor: Ligand Pharmaceuticals

Target Recruit Count: 48

Registration Number: NCT02250222

Locations: 🇺🇸
Celerion, Inc, Tempe, Arizona, United States
🇺🇸
Clinical Pharmacology of Miami, Inc, Miami, Florida, United States
🇺🇸
Medpace Clinical Pharmacology, Cincinnati, Ohio, United States

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Placebo (Captisol®)
Drug: LGD-6972

First Posted Date: 2013-08-09

Last Posted Date: 2014-09-25

Lead Sponsor: Ligand Pharmaceuticals

Target Recruit Count: 56

Registration Number: NCT01919684

Locations: 🇺🇸
Medpace Clinical Pharmacology, Cincinnati, Ohio, United States

Compare Captisol-Enabled (CE) Budesonide + Azelastine Nasal Solution and Rhinocort Aqua + Astelin in an Environmental Exposure Chamber (EEC) Study of Allergic Rhinitis

Phase 2

Completed

Conditions: Seasonal Allergic Rhinitis

Interventions: Drug: Budesonide + Azelastine
Drug: Placebo

First Posted Date: 2009-07-17

Last Posted Date: 2012-10-04

Lead Sponsor: Ligand Pharmaceuticals

Target Recruit Count: 108

Registration Number: NCT00940953

Locations: 🇨🇦
Allied Research International - Cetero Research, Mississauga, Ontario, Canada

Compare CE-Budesonide Nasal Solution & Rhinocort Aqua in an EEC Study of AR

Phase 2

Completed

Conditions: Seasonal Allergic Rhinitis

Interventions: Drug: Budesonide
Drug: Placebo

First Posted Date: 2009-07-14

Last Posted Date: 2012-10-04

Lead Sponsor: Ligand Pharmaceuticals

Target Recruit Count: 65

Registration Number: NCT00938613

Locations: 🇨🇦
Allied Research International - Cetero Research, Mississauga, Ontario, Canada

Study of MB07811 in Subjects With Hypercholesterolemia

Phase 2

Withdrawn

Conditions: Hypercholesterolemia

Interventions: Drug: Placebo
Drug: MB07811

First Posted Date: 2009-04-09

Last Posted Date: 2011-08-12

Lead Sponsor: Ligand Pharmaceuticals

Target Recruit Count: 80

Registration Number: NCT00879112

Locations: 🇺🇸
Scripps Clinic, Clinical Research, San Diego, California, United States
🇺🇸
Jacksonville Center for Clinical Research, Jacksonville, Florida, United States
🇺🇸
University Clinical Research, Pembroke Pines, Florida, United States

and more 8 locations

The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation

Phase 2

Completed

Conditions: Bone Loss

Interventions: Other: Placebo
Drug: Lasofoxifene

First Posted Date: 2008-05-07

Last Posted Date: 2011-08-10

Lead Sponsor: Ligand Pharmaceuticals

Target Recruit Count: 51

Registration Number: NCT00674453

Locations: 🇬🇧
Pfizer Investigational Site, Sheffield, United Kingdom

A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension

Phase 2

Completed

Conditions: Hypertension

Interventions: Drug: placebo
Drug: PS433540
Drug: irbesartan

First Posted Date: 2008-03-13

Last Posted Date: 2011-09-16

Lead Sponsor: Ligand Pharmaceuticals

Target Recruit Count: 261

Registration Number: NCT00635232

Locations: 🇺🇸
Advanced Clinical Research 1000 Forrest Place Suite 2 Pell City, Pell City, Alabama, United States
🇺🇸
Premiere Pharmaceutical Research, LLC, Tempe, Arizona, United States
🇺🇸
Genova Clinical Research AZ, Tucson, Arizona, United States

and more 37 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy